Commentary on “Outcomes of Allogenic Umbilical Cord Mesenchymal Stem Cell Infusion for Liver Cirrhosis Due to Biliary Atresia After Kasai Operation” JPEDSURG-D-25-00654R2
Topic overview
This commentary discusses Vietnamese research on umbilical cord mesenchymal stem cell infusion as adjunctive therapy for biliary atresia patients post-Kasai operation. The study addresses a critical unmet need in managing progressive liver fibrosis in infants with advanced disease at presentation.
Key takeaways
- Allogeneic umbilical cord mesenchymal stem cells show promise as adjunct therapy for post-Kasai biliary atresia patients with advanced fibrosis.
- Study cohort had late Kasai operations (median 81 days) with 75% showing severe fibrosis (METAVIR F3-F4) at baseline.
- Cell-based therapy represents novel approach to address liver fibrosis progression in biliary atresia, a condition with limited treatment options.
- Vietnamese research team demonstrates feasibility of stem cell infusion in pediatric post-portoenterostomy liver disease management.
Keywords
Hashtags
Full article text
Full article text not available for this entry
How to cite: GlobalCastMD. Commentary on “Outcomes of Allogenic Umbilical Cord Mesenchymal Stem Cell Infusion for Liver Cirrhosis Due to Biliary Atresia After Kasai Operation” JPEDSURG-D-25-00654R2. GlobalCastMD Medical Library. 2025-09-05. https://library.globalcastmd.com/article/10945
Comments